C4X Discovery Holdings PLC
LSE:C4XD
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
7.8
18.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
C4X Discovery Holdings PLC
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | UK |
Market Cap | 30.3m GBP |
Net Margin |
43%
|
Country | US |
Market Cap | 1.3T USD |
Net Margin |
9%
|
Country | US |
Market Cap | 196.3B USD |
Net Margin |
14%
|
Country | US |
Market Cap | 170.3B USD |
Net Margin |
18%
|
Country | KR |
Market Cap | 66.5T KRW |
Net Margin |
24%
|
Country | CH |
Market Cap | 37.6B CHF |
Net Margin |
9%
|
Country | US |
Market Cap | 38.5B USD |
Net Margin |
22%
|
Country | US |
Market Cap | 36.7B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 26.4B USD |
Net Margin |
21%
|
Country | US |
Market Cap | 23B USD |
Net Margin |
17%
|
Country | US |
Market Cap | 22.3B USD |
Net Margin |
-36%
|
C4X Discovery Holdings PLC
Glance View
C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on C4X Discovery Holdings PLC's most recent financial statements, the company has Net Margin of 42.8%.